Reverie Labs’ Post

🎂 In 2023, we celebrated 5 years of #StartLab!   👋 When it first opened in March 2018, it could only accommodate 15 companies (HAYA Therapeutics, Gnubiotics Sciences and Volumina Medical were among the first residents).   Today, StartLab can host up to 25 companies in a 1000 m² space. A lot has changed in five years!   What hasn't changed, however, is that StartLab was — and still is — an ideal launchpad for small projects, new start-ups and intensive bootstrap periods.    👇 Discover key figures from the StartLab #community in this handy infographic taken from the Biopôle Review 2023!

🚀 Big News: Segmed Secures $10.4 Million Series A Funding! We are thrilled to share that Segmed has successfully raised a $10.4 million Series A funding round, spearheaded by iGan Partners and Advocate Health, with contributions from Castellan Group, LLC, Engine Health Capital, Bold Brain Capital, Fox Chase Cancer Center, and existing investors including Y Combinator, Nina Capital, Nova Capital, Blumberg Capital, and Expeditions Fund. The current Series A round follows a financing by Flashpoint Venture Capital received in 2023. This oversubscribed round signifies a major milestone in Segmed’s mission to revolutionize medical imaging solutions for AI development and real-world evidence. With this new investment, Segmed is set to enhance our footprint in healthcare AI, bringing medical imaging to the biopharmaceutical and life sciences industries. Our mission is to unlock diverse cohorts of imaging data to support AI development and clinical research, ultimately advancing global healthcare. 🔗 Learn more at https://hubs.li/Q02NpKnl0 Thank you to all our partners and investors for believing in our vision. Together, we’re not just imagining the future of healthcare—we're building it. #HealthcareInnovation #AIinHealthcare #MedicalImaging #RealWorldData #SeriesAFunding #Segmed

🌟 Exciting News 🌟 We are thrilled to announce a strategic investment from Labcorp Venture Fund and the Alzheimer's Drug Discovery Foundation (ADDF) in an #oversubscribed financing round led by DigitalDx Ventures, and joined by existing investors EIFO, and Hybsch Connect. These partnerships are a powerful testament to the groundbreaking science behind our #GLXSignaturePlatform and asset pipeline—a unique fusion of vascular biology and AI technology aimed at revolutionizing the care of people with neurological conditions. Our mission is to deliver transformative value for healthcare providers, pharma, and payors- and, above all, patients in need of more precise medicine. For more information, Press Release: https://lnkd.in/d_FjERTe #GLXAnalytix #Labcorp #ADDF #HealthcareInnovation #PersonalizedMedicine #Biomarkers #AI #DigitalDx #EIFO #HealthcareTransformation Brian DellaValle

Drug development, AI, and VC dollars... My colleague, Shaurya Gilani and I had the delight to sit down with Uplaksh Kumar (who wears many many hats across Foresite Capital) to discuss all these topics and more! Check out the full piece here: https://lnkd.in/eGFZCxmv What were our takeaways, you ask? Tremendous excitement for AI in drug discovery and development, particularly for molecular design and identifying drug targets (e.g., Xaira, which Foresite Labs incubated) Optimism for CGT and advanced diagnostics, especially the use of combo therapies and multi-cancer detection tests increasing predictive value Green shoots and some optimism for venture funding in life science tools and diagnostics (fun fact - overall life science venture capital deployment in 2024 is on track to be one of the top years on record) Its not well known but in addition to our strategy consulting work, we work with Austin Duke at BroadOak Capital on an early-stage venture fund to support tools companies. Part of our firm ethos of being industry participants as much as possible to help drive the precision medicine revolution 💪 #pharma #drugdevelopment #venturecapital

🌟 Milestone Alert: Segmed Raises $10.4M in Series A! 🚀 What a journey it’s been! Today, I'm beyond thrilled to share that Segmed, Inc. has raised $10.4 million in our Series A funding round, marking a pivotal moment in our mission to reshape healthcare research and innovation. This achievement was made possible by the incredible support of our lead investors, iGan Partners and Advocate Health, alongside new investors Castellan Group, LLC, Engine Health Capital, Bold Brain Capital, Fox Chase Cancer Center, and our dedicated backers Y Combinator, Nina Capital, Nova Capital, Blumberg Capital, Expeditions Fund, and Flashpoint Venture Capital. But this isn’t just about the numbers—it’s about the vision. We’re on a quest to unlock the power of #Medicalimaging and real-world data, driving innovation in #AI and transforming how the biopharmaceutical and life sciences industries approach clinical research. 💡 Curious about our next steps? Check out the full story here: https://lnkd.in/gZWYVTek A heartfelt thank you to the brilliant Segmed team, partners, investors, advisors, and supporters. Together, we’re not just participating in the future of healthcare—we’re creating it. #RWiD #RWD #SeriesA #Segmed

While mRNA modification has significantly mitigated inflammation and toxicity in RNA therapies, leading to successful market entries, the same success has not been fully mirrored in lipid-based delivery systems. The toxicity and inflammatory responses associated with these delivery vehicles remain critical hurdles, as evidenced by numerous clinical trial failures involving LNPs and other advanced delivery systems. At Orion Therapeutics, our cutting-edge lipopeptide delivery platform addresses these challenges by enhancing the therapeutic index and reducing toxicity, offering a robust solution for the most challenging hurdles in genetic medicine - The Issue of Delivery. Recognizing the potential of our platform to address a wide range of therapeutic areas, we are actively seeking opportunities to out-license our technology. This strategic approach allows us to collaborate with partners aiming to harness the power of RNA therapies in their own pipelines, expanding the impact of our innovations across the biotech landscape and contributing to the advancement of genetic medicine. Join us at the MassBio Align Summit to explore how our technology is setting new benchmarks; we will be presenting at 10:50 AM tomorrow in the East Tower room. #AlignSummit24 #AlignSummit #AIDrugDiscovery #LNP #RNA

Enveda Biosciences Secures $55 Million In New Financing Round Learn more & get our take 👇 https://lnkd.in/d_-e9QfD “At Premji Invest, we seek to partner with exceptional teams to build companies that can create long-term value. We are excited by Enveda’s potential to deliver new, safe and efficacious treatments for complex conditions, pushing the boundaries of AI and ML in life sciences.” — Sandesh Patnam, Managing Partner at Premji Invest “We’re proud to support Enveda as we see its potential for long-term, open-ended growth due to the broad utility of their technology for solving some of the toughest challenges facing human and planetary health.” — Morgan Samet, Partner and Co-Head at Lingotto Investment Management “The investors who joined in this round recognize our rapid progress, as well as our expansive potential and vision. In combination with our deep bench of top tier investors, we are in an ideal position to advance our novel medicines into the clinic and to bring hope to waiting patients.” — Viswa Colluru, PhD, Ph.D., CEO and Founder at Enveda #funding #biosciences #SoHCNews

Unlearn.AI has successfully raised $50M in a Series C round led by Altimeter Capital, with significant contributions from Radical Ventures, Wittington Ventures, Mubadala Capital, EPIC Ventures, and Necessary Ventures Capital. This milestone enables Unlearn to further its groundbreaking work in AI for clinical trials, notably through the development of digital twins that promise to streamline and enhance the efficiency of these crucial studies. This funding not only supports Unlearn's growth and expansion into new therapeutic areas but also underscores the potential of AI to transform medical research by making it more efficient and effective. https://lnkd.in/eSd3UAtY #UnlearnAI #ClinicalTrials #DigitalTwins #AIInHealthcare #SeriesCFunding

Top Venture Funding Events October 18, 2024 Here’s a look at the latest companies securing major funding and driving innovation: Aktis Oncology ($175M - Series B): Developer of novel alpha radiotherapies aimed at improving solid tumor treatment efficacy while limiting toxicity. Alchemy ($31M - Seed): Healthcare company supporting safety net clinics with in-house pharmacies and clinical pharmacy programs. https://lnkd.in/eqm9MA6U eGenesis, Inc. ($191M - Series D): Life sciences company using CRISPR technology to develop safe and effective human transplantable organs and tissues. Perry Weather ($15M - Series B): Modern weather safety and operations platform, providing software and warning systems for weather-impacted industries. Splitero ($300M - Strategic): Financial technology company giving homeowners options to access home equity through shared appreciation. Superluminal Medicines Inc. Medicines ($120M - Series A): Generative biology and chemistry company accelerating the creation of medicines using machine learning and big data. If you represent one of these companies, please feel free to add a link to an explainer video, website, or tell us more in the comments. #VC #Funding #Venture #News

How do you turn #AI conversations into concrete progress? Next week, Tharindi Hapuarachchi, PhD will represent #TeamGenerate at #Benchtalk 2024, joining Will Weiss of Eli Lilly and Company and Ron Hause of Shape Therapeutics Inc. They’ll dive into the toughest challenges in R&D—like overcoming data quality issues—and share how to get your data AI-ready and integrated into your workflows. This is where AI meets real-world application. Don’t miss it. Get the details here: https://lnkd.in/e-j2YKUb #GenerativeAI | #ProgrammingBiology